MBRX (Moleculin Biotech) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is Moleculin Biotech EBITDA Margin %?

Moleculin Biotech MBRX +2.05% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Moleculin Biotech ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Moleculin Biotech's EBITDA for the three months ended in Mar. 2026 was $-7.87 Mil. Moleculin Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Moleculin Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Moleculin Biotech (NAS:MBRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Moleculin Biotech EBITDA Margin % Related Terms

Moleculin Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech EBITDA Margin % Chart

Moleculin Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

Moleculin Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MBRX vs ICU, LEXX, INTI: EBITDA Margin % Comparison

For the Biotechnology subindustry, Moleculin Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moleculin Biotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's EBITDA Margin % falls into.

Save Embed

30GF Score

Moleculin Biotech Inc MBRX

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Moleculin Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Moleculin Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-25.013	/	0
	=	%

Moleculin Biotech's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-7.866	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Moleculin Biotech (MBRX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #999999 out of 944 companies in the Biotechnology industry.

Is Moleculin Biotech's EBITDA Margin % too high?

Moleculin Biotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, Moleculin Biotech ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Moleculin Biotech's EBITDA Margin % compare to ICU and LEXX?

According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #999999 out of 944 companies for EBITDA Margin %. This places Moleculin Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Moleculin Biotech stock overvalued right now?

Moleculin Biotech (MBRX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies ICU LEXX INTI MTVA CVKD HCWB OSRH COCP HOOK LNAI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0K2H:UK

Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website https://www.moleculin.com

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

30GF Score

Get the complete analysis for MBRX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00

Price

View MBRX Analysis

See EBITDA Margin % data for all stocks →